Firefly Neuroscience (AIFF) AI Stock Analysis

• Market Cap: $42.57M
• Dividend Yield: N/A
• Average Volume (3M): 1.30M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.58
• Revenue Growth: -51.08%
• EPS Growth: 11.31%
• Country: US
• Employees: 13
• Sector: Technology
• Sector Strength: 84
• Industry: Software - Application
• EPS (TTM): -2.64
• Shares Outstanding: 12,861,098
• 10 Day Avg. Volume: 200,710
• 30 Day Avg. Volume: 1,304,022
• PEG Ratio: 0.49
• Price to Book (P/B): 366.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.60
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 186.01
• Enterprise Value/Gross Profit: -26.13
• Enterprise Value/Ebitda: -2.30
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 25 Underperform
• Price Target: ―

Firefly Neuroscience's stock is heavily impacted by its significant financial instability, marked by persistent losses, negative equity, and cash flow deficits. The bearish technical indicators further weigh down the score. Although the acquisition of Evoke Neuroscience presents a positive strategic move, it does not sufficiently mitigate the fundamental financial and valuation challenges. Overall, the stock faces a challenging outlook with limited upside potential.

Firefly Neuroscience Business Overview & Revenue Model

Company Description

Firefly Neuroscience (AIFF) is a pioneering company operating in the intersection of artificial intelligence and neuroscience. The company focuses on developing cutting-edge neurotechnology products that enhance cognitive performance and mental health. Firefly Neuroscience offers a range of products, including brain-computer interface (BCI) devices and neurofeedback systems, aimed at both clinical and consumer markets, enabling users to optimize brain function and improve mental well-being.

How the Company Makes Money

Firefly Neuroscience generates revenue through the sale of its neurotechnology products and solutions. The company targets both individual consumers and healthcare institutions, offering devices that are either purchased outright or through subscription-based models. Key revenue streams include direct sales of brain-computer interface devices, licensing of proprietary neurofeedback software, and subscription services for ongoing access to cognitive enhancement programs. Additionally, Firefly Neuroscience may engage in strategic partnerships with healthcare providers and technology companies to expand its market reach and enhance product offerings, thereby contributing to its revenue growth.

Firefly Neuroscience Financial Statement Overview

Summary

Firefly Neuroscience is currently facing substantial financial challenges, characterized by persistent losses, negative equity, and cash flow deficits. The financial outlook is concerning, with significant risks associated with its current leverage and inability to generate positive cash flows from operations.

Income Statement

Firefly Neuroscience demonstrates a significant challenge in achieving profitability, with consistent negative net income and EBIT over the years. The company experienced a sharp decline in revenue from 2023 to 2024, paired with widening losses, indicating challenges in revenue generation and cost management.

Balance Sheet

The balance sheet shows a concerning negative stockholders' equity, indicating the company is over-leveraged relative to its assets. The debt-to-equity ratio is also not calculable due to negative equity, further highlighting financial instability.

Cash Flow

Cash flow analysis reveals negative free cash flow throughout the years, suggesting ongoing operational cash deficits. Although the company has managed to secure financing, operational cash flow remains negative, indicating a reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
108.00K	498.00K	0.00	32.00K
	Gross Profit
41.00K	498.00K	0.00	32.00K
	EBIT
-10.05M	-3.08M	-3.33M	-4.65M
	EBITDA
-10.32M	-2.58M	-3.20M	-3.82M
	Net Income Common Stockholders
-10.46M	-2.60M	-3.79M	-4.38M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.81M	2.14M	58.00K	653.00K
	Total Assets
4.60M	2.64M	135.00K	953.00K
	Total Debt
694.00K	0.00	0.00	1.79M
	Net Debt
-1.12M	-2.14M	-58.00K	1.14M
	Total Liabilities
4.98M	2.53M	2.25M	3.97M
	Stockholders Equity
-375.00K	109.00K	-2.11M	-3.01M
Cash Flow		Free Cash Flow
-6.57M	-2.56M	-2.89M	-3.82M
	Operating Cash Flow
-6.16M	-2.17M	-2.89M	-3.82M
	Investing Cash Flow
-477.00K	-386.00K	262.00K	1.60M
	Financing Cash Flow
6.30M	4.64M	2.04M	2.04M

Firefly Neuroscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.23
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Negative. The current price of 3.23 is below the 20-day moving average (MA) of 3.28, above the 50-day MA of 3.23, and below the 200-day MA of 3.68, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.75 is Neutral, neither overbought nor oversold. The STOCH value of 52.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIFF.

Firefly Neuroscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MNDO	69 Neutral	$29.94M	8.02	18.26%	14.96%	-5.54%	-27.40%
LGCL	66 Neutral	$49.19M	8.46	40.01%	―	―	―
Sector *	62 Neutral	$11.93B	10.60	-7.51%	3.00%	7.40%	-8.09%
AWRE	53 Neutral	$35.86M	―	-16.05%	―	-9.72%	25.68%
SWVL	50 Neutral	$47.27M	―	-198.18%	―	-24.70%	-371.57%
AIFF	25 Underperform	$42.57M	―	-748.64%	―	-51.08%	11.31%

Firefly Neuroscience Corporate Events

Firefly Neuroscience Acquires Evoke Neuroscience for $6 Million

On April 30, 2025, Firefly Neurosciences Inc. acquired Evoke Neuroscience, Inc., a medical device company, for $6 million in a deal consisting of cash and stock. This acquisition significantly expands Firefly’s database, intellectual property, and commercial footprint, marking a major step toward building a proprietary foundation model of the human brain. The transaction closed on May 1, 2025, and is expected to enhance Firefly’s industry positioning by leveraging Evoke’s technology and resources, including a large proprietary database and numerous patents. This strategic move aligns with Firefly’s goal of rapid growth and innovation in brain health solutions.

Spark’s Take on AIFF Stock

According to Spark, TipRanks’ AI Analyst, AIFF is a Underperform.

Firefly Neuroscience faces significant financial hurdles, including widening losses and negative equity, which are the most critical factors impacting its stock score. The technical analysis further highlights bearish trends, with the stock trading below key moving averages. The negative P/E ratio and absence of dividends further reflect valuation concerns. Overall, the financial instability and bearish technical indicators result in a low stock score.

To see Spark’s full report on AIFF stock, click here.

Firefly Neuroscience Appoints New President and COO

Firefly Neuroscience has approved the issuance of shares to BPY Limited and Nomis Bay Ltd. as part of inducement agreements, and entered into settlement agreements with Ian McLean and 1128526 Alberta Ltd. to resolve employment-related disputes. Additionally, David DeCaprio has been appointed as the President and COO, with Arun Menawat filling his previous board committee roles. These developments are part of strategic moves to strengthen company operations and resolve outstanding legal matters.

Spark’s Take on AIFF Stock

According to Spark, TipRanks’ AI Analyst, AIFF is a Underperform.

Firefly Neuroscience faces significant financial hurdles, including widening losses and negative equity, which are the most critical factors impacting its stock score. The technical analysis further highlights bearish trends, with the stock trading below key moving averages. The negative P/E ratio and absence of dividends further reflect valuation concerns. Overall, the financial instability and bearish technical indicators result in a low stock score.

To see Spark’s full report on AIFF stock, click here.

Firefly Neuroscience Appoints Greg Lipschitz as CEO

Firefly Neuroscience has appointed Greg Lipschitz as the new Chief Executive Officer, effective March 26, 2025. The company has entered into an Executive Employment Agreement with Lipschitz, which includes a base salary of $300,000 per year, potential bonuses, and stock units. The agreement outlines conditions for severance and equity compensation in case of termination, and includes a confidentiality agreement to protect the company’s proprietary information.

Firefly Neuroscience Appoints New Chairman Amid Leadership Changes

On March 10, 2025, Greg Lipschitz resigned as Executive Chairman of Firefly Neuroscience, Inc., though he remains a director. His resignation was not due to any disagreements with the company’s operations. Arun Menawat was elected as the new Chairman, leading to changes in board committee memberships, including David DeCaprio and Stella Vnook taking new roles. Additionally, Paul Krzywicki, the CFO, received stock options and restricted stock units under the company’s 2024 Long-Term Incentive Plan.